QUININE SULFATE

Post-LOE

quinine sulfate

Teva

ANDAORALCAPSULE

Approved

Sep 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

QUININE SULFATE (quinine sulfate) by Teva is [ see microbiology () ]. Approved for uncomplicated plasmodium falciparum malaria. First approved in 2012.

Drug data last refreshed 18h ago

Mechanism of Action

[ see Microbiology () ].

Indications (1)

uncomplicated Plasmodium falciparum malaria

Clinical Trials (1)

NCT05808231N/AUnknown

Effectiveness and Safety of Quinine Sulfate as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia ( DEAL-COVID19 )

Started Apr 2021

100 enrolled

COVID-19

Company

Worked on QUININE SULFATE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.